In a groundbreaking development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), the Phase 3 SEQUOIA-HCM trial has demonstrated that
In a groundbreaking analysis of the STEPHFpEF programme, researchers have discovered that semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA),
In a thought-provoking presentation, Dr. Milton Packer, a renowned expert in the field of cardiology, shed light on the groundbreaking
Professor Mark Petrie from the University of Glasgow and Glasgow Royal Infirmary presented an overview of the future directions and
This paper was presented on the final day of the 2022 Scientific Sessions of the Society for Cardiovascular Angiography and
This paper was presented on the final day of the 2022 Scientific Sessions of the Society for Cardiovascular Angiography and
This paper was presented on the final day of the 2022 Scientific Sessions of the Society for Cardiovascular Angiography and
This paper was presented on the final day of the 2022 Scientific Sessions of the Society for Cardiovascular Angiography and
This paper was presented on the final day of the 2022 Scientific Sessions of the Society for Cardiovascular Angiography and
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic stenosis and is now the main treatment of choice
© All rights reserved.